Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABCL 
Abcellera Biologics Inc (ABCL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: ABCL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.43
1 Year Target Price $8.43
| 6 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.78% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.20B USD | Price to earnings Ratio - | 1Y Target Price 8.43 |
Price to earnings Ratio - | 1Y Target Price 8.43 | ||
Volume (30-day avg) 9 | Beta 0.36 | 52 Weeks Range 1.89 - 4.33 | Updated Date 07/12/2025 |
52 Weeks Range 1.89 - 4.33 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1479.58% |
Management Effectiveness
Return on Assets (TTM) -12.94% | Return on Equity (TTM) -15.6% |
Valuation
Trailing PE - | Forward PE 27.47 | Enterprise Value 659504502 | Price to Sales(TTM) 51.78 |
Enterprise Value 659504502 | Price to Sales(TTM) 51.78 | ||
Enterprise Value to Revenue 28.53 | Enterprise Value to EBITDA 5.3 | Shares Outstanding 298484992 | Shares Floating 202402451 |
Shares Outstanding 298484992 | Shares Floating 202402451 | ||
Percent Insiders 22.97 | Percent Institutions 44.79 |
Upturn AI SWOT
Abcellera Biologics Inc
Company Overview
History and Background
Abcellera Biologics Inc. was founded in 2012. It focuses on antibody discovery using its technology platform to search and analyze natural immune systems to find antibodies for therapeutic development.
Core Business Areas
- Antibody Discovery: Abcellera's primary business involves partnering with pharmaceutical and biotech companies to discover and develop therapeutic antibodies. They offer end-to-end solutions, from target validation to lead candidate selection.
- Technology Platform Development: Abcellera continuously invests in and develops its proprietary technology platform, which includes microfluidics, machine learning, and single-cell analysis, to improve the speed and efficiency of antibody discovery.
Leadership and Structure
Abcellera is led by CEO Carl Hansen. The company has a structured organizational framework focusing on technology development, partnership management, and research & development.
Top Products and Market Share
Key Offerings
- Antibody Discovery Platform: Abcellera's primary offering is its integrated antibody discovery platform. While specific market share data is not publicly available, it competes with other antibody discovery service providers and biotech companies with in-house discovery capabilities. Competitors include companies like Ligand Pharmaceuticals (LGND) and distributed lab CROs like Charles River (CRL).
- Therapeutic Programs: Abcellera partners with pharmaceutical companies to discover antibodies that are then developed into therapeutic programs. Revenue is generated through upfront payments, milestone payments, and royalties on sales of approved drugs derived from these collaborations. Competitors depend on the target pursued.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing rapid growth, driven by increasing demand for innovative therapies and advancements in biotechnology. Antibody therapies represent a significant portion of this market.
Positioning
Abcellera is positioned as a technology leader in antibody discovery, leveraging its advanced platform to offer faster and more efficient solutions to its partners. They aim to de-risk and accelerate the drug discovery process.
Total Addressable Market (TAM)
The global antibody therapeutics market is estimated to be in the hundreds of billions of dollars. Abcellera's TAM is the segment related to antibody discovery services, which represents a substantial portion of the overall market. Their position is to capture a significant share by providing advanced technology solutions.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Strong partnerships with leading pharmaceutical companies
- Data-driven approach to antibody discovery
- Experienced management team
Weaknesses
- Reliance on partnerships for revenue generation
- High R&D costs
- Limited control over downstream development and commercialization of partnered programs
- Relatively new company, execution risk
Opportunities
- Expanding partnerships with additional pharmaceutical and biotech companies
- Developing new applications for its technology platform
- Capitalizing on the growing demand for antibody therapies
- Expanding into new therapeutic areas
Threats
- Competition from other antibody discovery companies
- Technological advancements that could render its platform obsolete
- Failure of partnered programs in clinical trials
- Economic downturn affecting pharmaceutical R&D spending
Competitors and Market Share
Key Competitors
- LGND
- CRL
- JNJ
- LLY
- REGN
Competitive Landscape
Abcellera's advantage lies in its technology platform, which allows for rapid and efficient antibody discovery. However, it faces competition from larger, more established pharmaceutical companies with in-house discovery capabilities and other antibody discovery service providers.
Growth Trajectory and Initiatives
Historical Growth: Abcellera's historical growth has been driven by an increasing number of partnerships and the advancement of partnered programs.
Future Projections: Future growth is expected to be driven by further expansion of its technology platform, securing additional partnerships, and the potential for royalties from successful therapeutic programs.
Recent Initiatives: Recent initiatives include investments in new technology platforms, expanding its research facilities, and forming new strategic partnerships.
Summary
Abcellera is an innovative antibody discovery company with a strong technology platform and strategic partnerships. Its reliance on partnerships poses some risk, but its potential for future growth is significant. The company should focus on diversifying its partnerships and driving partnered programs through clinical trials. Competition and technological advancements are key risks to monitor.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly. Consult with a financial advisor before making any investment decisions. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abcellera Biologics Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2020-12-11 | CEO, President & Chairperson Dr. Carl L.G. Hansen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 596 | Website https://www.abcellera.com |
Full time employees 596 | Website https://www.abcellera.com | ||
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.